Today's Date: March 28, 2024
Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children with the Introduction of bébé Bottoms™   •   UC Berkeley FHL Vive Center Teams Up with BeamNG   •   Planet to Provide Carbon Mapper, Inc. with Hyperspectral Data Until 2030   •   Sypher Secures Strategic Partnership with FAIA to Fuel Growth   •   Paralyzed Veterans of America to honor former Senator Elizabeth Dole with 2024 Gordon H. Mansfield Congressional Leadership Awar   •   BNSF Railway builds upon safety record by utilizing virtual reality for training   •   Gale Primary Sources Release Four New Archives Devoted to Contributions from Underrecognized Communities   •   Federal Home Loan Bank of Dallas and Wells Fargo Bank Award $850K for Rio Manor Apartments Renovation   •   VIRGIN HOTELS CHAMPIONS INCLUSIVE TRAVEL FOR NEURODIVERSE TRAVELERS   •   Chevron Announces Opening of Fab Labs at HBCUs   •   University of Phoenix Receives Arizona Veteran Supportive Campus Recertification   •   80 M/other Artists Converge for MICAfest 2024 in Northampton, MA this May   •   Bill Introduced in Minnesota Would Increase Access To Genetic Testing   •   American Water Charitable Foundation Announces National Partnership With American Red Cross With $250,000 Donation   •   PMI Foods Gives Easter Donation of 15,000 Pounds of Prime Rib to New Life Church in Arkansas   •   Impacts of Extreme Weather on Interior Design Examined in New Research   •   More $10-a-day child care spaces   •   New Report Shows Massachusetts Customers Could Have Saved Hundreds of Millions in 2024 Through Competitive Energy Supply   •   Danimer Scientific Announces Fourth Quarter and Full Year 2023 Results   •   Pushing Policy: Women Uniting for Legislative Change; Four Trailblazing women at the forefront of the Quad Caucus
Bookmark and Share

SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encou

SAN DIEGO , March 23 /Businesswire/ - Robbins Geller Rudman & Dowd LLP announces an investigation into potential violations of U.S. federal securities laws by Sarepta Therapeutics, Inc. (NASDAQ: SRPT) focused on whether Sarepta and certain of its top executive officers made false and misleading statements and/or failed to disclose material information to investors.

If you have information that could assist in this investigation or if you are a Sarepta investor who suffered a loss and would like to learn more, you can provide your information here:

https://www.rgrdlaw.com/cases-sarepta-therapeutics-inc-securities-investigation-srpt.html

You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.

THE COMPANY: Sarepta is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. Sarepta is developing SRP-9001 (delandistrogene moxeparvovec), an investigational gene transfer therapy intended to deliver SRP-9001 to muscle tissue for the targeted production of functional components of dystrophin.

THE REVELATION: On March 16, 2023, Sarepta issued a press release stating that “at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration’s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.” Following this news, the price of Sarepta stock fell by approximately 18%.

ABOUT ROBBINS GELLER: Robbins Geller is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report for recovering more than $1.75 billion for investors in 2022 – the third year in a row Robbins Geller tops the list. And in those three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than double the amount recovered by any other plaintiffs’ firm. With 200 lawyers in 9 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.


STORY TAGS: California, Legal, Professional Services, Lawsuit, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News